HOME >> BIOLOGY >> NEWS
Improved NIST SRM aids lead poisoning detection

od obtained from goats. The red blood cell system of an adult goat is much closer to that of a human, making it a better model for assessing proficiency for erythrocyte protoporphyrin, a biomarker of lead exposure. NISTs partner in developing 955c, the New York State Department of Healths Wadsworth Center Lead Poisoning Laboratory, dosed adult goats with lead acetate to produce blood pools containing lead physiologically bound to red blood cells.* The new SRM provides a better match than its predecessor to the blood samples clinicians analyze. The lead concentrations were determined by NIST using highly specialized methodology that resulted in high accuracy and low measurement uncertainty.

The changing goal line for blood lead concentration makes SRM 955c especially useful to laboratories. The lowest lead concentration level in the previous standard was 4 micrograms per deciliter or 40 parts per billion. In contrast, the lowest lead concentration level of SRM 955c is 0.4 microgram per deciliter or four parts per billion, the level of lead in an undosed animal. It is intended to represent the natural level of lead in an unexposed human population (although it is not yet known if any lead is naturally present in human blood). The lowest concentration in the SRM is 25 times lower than the DHHS 2010 goal, and will enable the development of next generation clinical methods that will be needed to accurately measure blood lead levels in children as progress is made toward eliminating lead exposure.

In addition to lead, levels two through four of SRM 955c contain added amounts of arsenic, cadmium, mercury, methylmercury and ethylmercury to facilitate future efforts to develop clinical methods to measure these toxins in human blood. At present, NIST provides information values only for the concentrations of cadmium and total mercury (including methylmercury and ethylmercury.) As values become available for arsenic, methylmercury and ethylmercury, the cert
'"/>

Contact: John Blair
john.blair@nist.gov
301-975-4261
National Institute of Standards and Technology (NIST)
3-Aug-2007


Page: 1 2 3

Related biology news :

1. Improved predictions of warming-induced extinctions sought
2. Improved imaging for identifying breast cancer in overweight women
3. Improved speech without vocal cords
4. Improved blood safety measures from Pall can increase platelet availability
5. Improved statistical tools reveal many linked loci
6. Improved process of drying lumber may save millions
7. Improved cancer treatments aim of new biology research program
8. Improved recipe for magnetic brain stimulation
9. Improved molecular switch could serve as sensor, medical tool
10. Leading the fight against food poisoning
11. Dipstick test could reduce risk of food poisoning by rapidly detecting spoilage

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Improved NIST SRM aids lead poisoning detection

(Date:10/22/2014)... Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... services, today reported financial results for its third quarter ended ... of 2014 was $6.0 million, an increase of 40% compared ... income in the third quarter of 2014 was $4.1 million ... Higher operating income in the current three month period was ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by product ... Table-top Counters) by End-user (Inpatient Pharmacy Automation, Outpatient ... 2019” analyzes and studies the major market drivers, ... and the Rest of the World (RoW). , ... through 300 pages and in-depth TOC on "Pharmacy ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
(Date:10/20/2014)... Md. , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Zola P. Horovitz , Ph.D., from its board of directors ... board in August 2003, and served as its chairman from ... served on the Nominating and Corporate Governance and Audit Committees ... for more than a decade of dedicated service to GenVec, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
Cached News: